Elizabeth Williams, MD
Urogynecology and Reconstructive Pelvic Surgery · St. Louis, MONPI 1790802429
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $162,061 of the $194,889 with a category attached, or 83.2%. Boston Scientific accounts for 66.7% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $42,355 and has fallen 50.6% since, to $20,909 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $454.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$130K
- Medtronic$51K
- Caldera Medical, Inc$5K
- Urovant Sciences Inc$3K
- Valencia Technologies Corporation$902
- AbbVie$894
- plus $3K from 30 others
Across 90 payments — averaging $3547.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bluewind Medical$318K
- Medtronic$1K
What the payments were for
- Consulting fees$5,7483%
- Speaking & faculty fees$162,06183%
- Travel & lodging$17,7009%
- Food & beverage$9,1545%
- Education$2250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 144 | $130,080 |
| Medtronic(2 entities) | 105 | $51,188 |
| Caldera Medical, Inc | 2 | $5,398 |
| Urovant Sciences Inc | 12 | $3,435 |
| Valencia Technologies Corporation | 2 | $902 |
| AbbVie(2 entities) | 55 | $894 |
| Astellas Pharma US Inc | 27 | $508 |
| Johnson & Johnson(2 entities) | 21 | $502 |
| Accord Healthcare, Inc. | 4 | $318 |
| Urogen Pharma, Inc. | 2 | $255 |
| KARL Storz Endoscopy-america | 3 | $211 |
| Coloplast | 3 | $205 |
| Olympus America Inc. | 1 | $129 |
| Blue Earth Diagnostics | 6 | $108 |
| Myovant Sciences Inc. | 4 | $91 |
| Bayer | 5 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Laborie Medical Technologies Corp. | 4 | $61 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Axonics, Inc. | 2 | $41 |
| Amgen | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Verity Pharmaceuticals Inc. | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| GSK | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Rochester Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solyx SIS System$52,085
- INTERSTIM$40,579
- SOLYX$32,419
- GENERAL FEMALE SUI$11,755
- UPSYLON$10,446
- Advantage System$9,900
- GENERAL PELVIC ORGAN PROLAPSE$8,625
- Desara$5,398
- Vertessa$4,798
- GEMTESA$3,375
- GENERAL - THERAPIES$1,989
- eCoin Device Kit$895
- VASCULAR$143
- RYBREVANT$136
- CARVYKTI$136
- JELMYTO$133
- iTIND System$129
- BOTOX$125
- ZUSDURI$121
- SPECTRA WAVEWRITER$110
How this compares
$194,889 in reported general payments places this provider in the 95th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Missouri.
See all urogynecology and reconstructive pelvic surgery providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 412 | $307,824 |
| GemtesaVibegron | 249 | $189,003 |
| Mirabegron ErMirabegron | 55 | $33,558 |
| Trospium Chloride ErTrospium Chloride | 110 | $15,802 |
| Trospium Chloride | 181 | $9,680 |
| Methenamine Hippurate | 124 | $9,457 |
| Estradiol | 124 | $8,475 |
| Solifenacin Succinate | 58 | $2,570 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $1,414 |
| Bethanechol Chloride | 11 | $1,351 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 111 | $1,336 |
| Cephalexin | 105 | $858 |
| Trimethoprim | 21 | $666 |
| Desmopressin Acetate | 13 | $658 |
| CefuroximeCefuroxime Axetil | 71 | $607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $508 | $307,824412 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $61 | $189,003249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Missouri.
Other urogynecology and reconstructive pelvic surgery in St. Louis
- Denicia DwaricaColumbia$19K
- Dionysios VeronikisSaint Louis$6K
- Raymond FosterColumbia$6K
- Ian RosbrughNorth Kansas City$5K
- Jerry LowderSaint Louis$4K
- Stephen WassingerKansas City$3K
- Nia JenkinsKansas City$3K
- Richard HillKansas City$3K
- Joe ShiSaint Louis$3K
- Alec Szlachta-McginnSaint Louis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.